Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The following milestones mark important progress in the consolidated federal litigation: Increased evidentiary standards for gastroparesis claims: Courts require plaintiffs alleging gastroparesis to support claims with objective gastric-emptying tests rather than symptoms alone, raising the bar for admissible medical evidence Daubert hearings on expert testimony: May 2025 hearings will determine whether plaintiffs medical experts can testify about causation potentially decisive rulings that could strengthen or weaken thousands of claims Short-form complaint process adoption: MDL implemented streamlined filing procedures to manage the influx of new cases efficiently while maintaining procedural fairness Monthly status conferences throughout 2025: Regular court meetings ensure ongoing case management and coordination as parties work through challenging scientific and legal issues In September 2025, Judge Marston allowed most plaintiffs claims to proceed after denying defendants motions to dismiss, including accusations that drugmakers failed to warn about gastrointestinal issues and misrepresented safety
In fact, studies have shown that it can have a positive effect on lowering blood pressure, especially in people who are overweight or have diabetes
Natural IGF-1 has a very short lifespan (half life) and likes to bind with other proteins that can change laboratory-based test results
However, at a societal level, I am concerned about adopting a wide-spread cultural position that injections and drugs are THE answer to the obesity epidemic to the point that we lose sight of the fact that obesity is a disease of lifestyle and environment, and that we must improve the way we live if we are to truly succeed in forcing obesity towards extinction
- :
Diabetes Metab Res Rev (2019) 35(7):e3168
